Drugmaker Eli Lilly says its daily oral GLP-1 pill may help people who have obesity and people with Type 2 diabetes lose ...

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes ...

Viking's 40% crash over fixable dosing issues ignores its best-in-class 12.2% oral weight loss and Phase 3 momentum.

This episode of Pharma Pulse covers FDA findings of contamination and safety lapses at Novo’s Bloomington manufacturing plant ...

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

As GLP-1 adoption grows and new applications for the drugs come to light, experts say that could have sweeping impacts for ...

Novo Nordisk A/S (NYSE: NVO) is one of the Most Undervalued International Stocks According to Analysts. On August 19, TD ...

Lexicon is pivoting towards biotech research. LXRX stock is highly speculative. Read here for key updates on Pilavapadin ...

As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

Health-care companies fell as traders continued to flee the sector. Shares of companies such as UnitedHealth Group, Novo Nordisk and Eli Lilly, which are already in the red for 2025, sank further.

An FDA Form 483 cited unaddressed contamination, pest infestations, and equipment failures at manufacturer’s Bloomington, IN ...

Drugmaker Novo Nordisk received accelerated approval for the drug’s use in people with moderate to advanced liver scarring, ...